UNSPSC 51182049: Clostebol propionate

This classification denotes an anabolic steroid C22H31ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7JJ3052NOU, chemically known as androst-4-en-3-one, 4-chloro-17-(1-oxopropoxy)-, (17.beta.)-, but more generally known as clostebol propionate, which bears US NIH Compound Identifier 71586790. Most nations, for tariff and trade purposes, schedule clostebol propionate under HS 29372900 and SITC 54153. As of Q4 2014, CLOSTEBOL PROPIONATE remains US FDA's Preferred Term for this commodity.

SMILES: CCC(=O)O[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=C(C(=O)CC[C@]34C)CL)C.

UNSPSC 51182049 Clostebol propionate (Commodity) covers anabolic steroid pharmaceutical products, though recent state and local activity shows the code capturing broader generic multi-source pharmaceutical and over-the-counter product procurement rather than this specific substance alone. State and local governments use this code to procure pharmaceutical inventory through cooperative purchasing agreements and multi-award contracts that establish pricing and supply relationships with authorized wholesalers. Issuing bodies include state purchasing offices administering multistate cooperative vehicles and their participating member jurisdictions across multiple states. The Minnesota Department of Administration's Office of State Procurement, acting through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), represents the primary recent solicitation activity visible under this code.

MMCAP issued an RFP in January 2026 (S1070000015802, due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with distribution across participating state and local government facilities in Minnesota and Oregon. The procurement requires vendors to supply products through three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — with awards effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent weight), supported by fixed pricing, compliance with administrative fee and EDI requirements, and demonstrated pricing flexibility through flat-price, net-price formats (NF30, NF60, NF90), or WAC-minus structures. Vendors must certify current Good Manufacturing Practices compliance, Drug Supply Chain Security Act certification, and maintain contractual relationships with at least two of the three wholesalers with chargeback systems. The contract term runs two years for new responders with optional MMCAP extensions, and vendors must carry commercial general liability coverage of $5 million per occurrence and professional liability of $2 million.